TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex
暂无分享,去创建一个
R. Touraine | K. Budde | V. Cottin | S. Jóźwiak | R. Nabbout | P. D. de Vries | J. C. Kingswood | J. Ferreira | M. Feucht | A. Jansen | P. Curatolo | Seema Shah | F. O'callaghan | A. Macaya | Yukitoshi Takahashi | J. Lawson | M. Dahlin | M. Sauter | C. Hertzberg | E. Belousova | B. Zonnenberg | S. Youroukos | J. Qin | M. Benedik | R. Marques | C. Fladrowski | G. B. d'Augères | T. Carter | Valentin Sander | Lisa D’Amato
[1] T. Kvien,et al. Clinical recommendations , 2020, Oxford Textbook of Rheumatoid Arthritis.
[2] O. Devinsky,et al. Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. , 2018, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[3] J. Bissler,et al. Renal manifestation of tuberous sclerosis complex , 2018, American journal of medical genetics. Part C, Seminars in medical genetics.
[4] D. Krueger,et al. mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex , 2018, American journal of medical genetics. Part C, Seminars in medical genetics.
[5] J. French,et al. Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial. , 2018, The Lancet. Child & adolescent health.
[6] M. Davies,et al. Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide , 2017, Orphanet Journal of Rare Diseases.
[7] J. French,et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study , 2016, The Lancet.
[8] O. Witt,et al. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study , 2016, PloS one.
[9] A. Boonen,et al. OP0017 Medication Taking Behaviour of Allopurinol Treatment among Patients with Gout: A Retrospective Cohort Study in The Clinical Practice Research Datalink (CPRD) , 2016 .
[10] K. Kotulska,et al. Management of side effects of mTOR inhibitors in tuberous sclerosis patients , 2016, Pharmacological reports : PR.
[11] P. Bolton,et al. The clinical profile of tuberous sclerosis complex (TSC) in the United Kingdom: A retrospective cohort study in the Clinical Practice Research Datalink (CPRD). , 2016, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[12] P. J. Vries,et al. Neurological and neuropsychiatric aspects of tuberous sclerosis complex , 2015, The Lancet Neurology.
[13] O. Witt,et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. , 2014, The Lancet. Oncology.
[14] P. Bruzzi,et al. TOSCA – first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex , 2014, Orphanet Journal of Rare Diseases.
[15] D. Krueger,et al. Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference , 2013, Pediatric neurology.
[16] K. Kotulska,et al. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. , 2013, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[17] S. Jóźwiak,et al. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations. , 2013, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[18] David Chen,et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial , 2013, The Lancet.
[19] D. Krueger,et al. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma , 2013, Neurology.
[20] E. Thiele,et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial , 2013, The Lancet.
[21] A. Byars,et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. , 2010, The New England journal of medicine.
[22] S. Jóźwiak,et al. Tuberous sclerosis , 2008, The Lancet.
[23] Michael C. Wendl,et al. Argonaute—a database for gene regulation by mammalian microRNAs , 2005, BMC Bioinformatics.
[24] Christopher N Martyn,et al. Prevalence of tuberous sclerosis estimated by capture-recapture analysis , 1998, The Lancet.
[25] S. Segal,et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[26] A. Cook,et al. Talking points personal outcomes approach: practical guide. , 2012 .
[27] Paul Landais,et al. Extended Report , 2022 .